Autolus Therapeutics Plc (AUTL) has released an update to notify the public and investors about an entry into a material definitive agreement.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Autolus Therapeutics plc has entered into an underwriting agreement with Jefferies LLC and Truist Securities, Inc., launching a registered direct offering of 58.3 million American Depositary Shares at $6.00 each, aiming to raise $350 million. The offering, detailed in a recent SEC filing, is set to close around February 12, 2024, with standard closing conditions. This significant financial move, underpinned by customary legal agreements, indicates a robust step for the company in securing its financial future.
For further insights into AUTL stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
Trending Articles:
- “Next-Generation Brain-Computer Interface”: Microsoft Stock (NASDAQ:MSFT) Gains With New AI Possibilities
- “May Not Fit Squarely in Tesla’s Mission”: Tesla (NASDAQ:TSLA) Shareholders Pass on xAI Investment
- Uh-Oh: Starbucks Stock (NASDAQ:SBUX) Slips as it Discovers How Little the Coffeehouse Experience Matters